Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
Copyright © 2021. Published by Elsevier Ltd..
OBJECTIVES: Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary.
METHODS: Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire.
RESULTS: We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort.
CONCLUSIONS: In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.
| Errataetall: |
CommentIn: J Infect. 2022 Jun;84(6):e118-e119. - PMID 35245580 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
The Journal of infection - 83(2021), 5 vom: 01. Nov., Seite 559-564 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tré-Hardy, Marie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 30.11.2021 Date Revised 21.08.2022 published: Print-Electronic CommentIn: J Infect. 2022 Jun;84(6):e118-e119. - PMID 35245580 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.08.031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329808451 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329808451 | ||
| 003 | DE-627 | ||
| 005 | 20231225205926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.08.031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329808451 | ||
| 035 | |a (NLM)34437927 | ||
| 035 | |a (PII)S0163-4453(21)00433-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tré-Hardy, Marie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2021 | ||
| 500 | |a Date Revised 21.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2022 Jun;84(6):e118-e119. - PMID 35245580 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVES: Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary | ||
| 520 | |a METHODS: Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire | ||
| 520 | |a RESULTS: We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort | ||
| 520 | |a CONCLUSIONS: In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a mRNA-1273 vaccine | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 700 | 1 | |a Cupaiolo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Wilmet, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Antoine-Moussiaux, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Della Vecchia, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Horeanga, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Papleux, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Vekemans, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Beukinga, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Blairon, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 83(2021), 5 vom: 01. Nov., Seite 559-564 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2021 |g number:5 |g day:01 |g month:11 |g pages:559-564 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.08.031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2021 |e 5 |b 01 |c 11 |h 559-564 | ||